Similar Items: Pharmacokinetics of Certolizumab Pegol in Pregnancy: Results from the Open-Label CHERISH Study
- Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials)
- Effectiveness and Safety of Tofacitinib Up to 36 Months in Canadian Patients with Rheumatoid Arthritis: Final Results from the CANTORAL Study
- A Case of Neural Tube Defect in Early Pregnancy Following Sulfasalazine Exposure Without Folic Acid Supplementation
- Corrigendum “Exposure to arboviral infections and risk of rheumatoid arthritis: Findings from the MyEIRA population‐based case‐control study”
- Real-World Upadacitinib Persistence and Clinical Outcomes Among Canadian Patients with Inflammatory Arthritis from a Patient Support Program: The UPRAISE Study
- Achievement and Maintenance of Remission with Upadacitinib in Patients with Moderate-to-Severe Rheumatoid Arthritis in Italy: 1-Year Data from UPHOLD, a Prospective Real-World Observational Study